Home/Pipeline/MS Biomarker Development

MS Biomarker Development

Multiple Sclerosis (MS)

Pre-clinical/R&DActive

Key Facts

Indication

Multiple Sclerosis (MS)

Phase

Pre-clinical/R&D

Status

Active

Company

Progentec Diagnostics

About Progentec Diagnostics

Progentec Diagnostics is pioneering a data-driven, proactive approach to managing autoimmune diseases by integrating molecular diagnostics (proteomics) with digital biomarkers and remote monitoring. Its flagship aiSLE® DX tests, available through Mayo Clinic Laboratories, predict lupus flare risk up to 12 weeks in advance. The company also operates a significant digital patient community and research platform (LupusCorner) and is expanding its pipeline into MS and other autoimmune conditions. Its business model leverages diagnostic test revenue and digital tools to improve patient outcomes and support decentralized clinical research.

View full company profile

Therapeutic Areas

Systemic Lupus Erythematosus Multiple Sclerosis Autoimmune Diseases

Other Multiple Sclerosis (MS) Drugs

Drug	Company	Phase	Status
CYMS101	FibroBiologics	Preclinical	Active
Alpha-Cobratoxin (Pharmaceutical)	Nutra Pharma	Preclinical	Research
CNM-Au8	Clene	Phase 2	Active
Sequential Dialysis Technique	Halberd	Discovery	Conceptual
MS Treatment (with Cycle Vita)	Cycle Pharmaceuticals	Commercial	Active
GM6	Genervon Biopharmaceuticals	Planning	Active
Next-Gen CAR-Tregs	PolTREG	Preclinical	In Development
XT-150 (Preclinical)	Xalud Therapeutics	Preclinical	Active
MEK Inhibitor Program	Pasithea Therapeutics	Discovery	Research